US 12,453,755 B2
GIP/GLP1 agonist compositions
Vincent John Corvari, Carmel, IN (US); Christopher Sears Minie, Zionsville, IN (US); Dinesh Shyamdeo Mishra, Carmel, IN (US); and Ken Kangyi Qian, Carmel, IN (US)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jan. 25, 2024, as Appl. No. 18/422,177.
Application 18/422,177 is a continuation of application No. 17/741,067, filed on May 10, 2022, granted, now 11,918,623.
Application 17/741,067 is a continuation of application No. 16/441,329, filed on Jun. 14, 2019, granted, now 11,357,820, issued on Jun. 14, 2022.
Claims priority of provisional application 62/688,632, filed on Jun. 22, 2018.
Prior Publication US 2024/0226229 A1, Jul. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61M 5/20 (2006.01)
CPC A61K 38/16 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61M 5/20 (2013.01)] 14 Claims
 
1. A method of treating diabetes comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof, at a concentration from about 5 mg/mL to about 30 mg/ml; dibasic sodium phosphate at a concentration from about 0.67 to about 2.68 mg/ml; NaCl at a concentration from about 6.2 mg/ml to about 9.5 mg/ml; and optionally comprising from about 3.0 mg/ml to about 7.0 mg/ml phenol.